ombitsavir, paritaprevir, retrovir, and dasabuvir (Viekira Pak®, Viekira XR®)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of chronic hepatitis C, genotype 1a and 1b without cirrhosis or with compensated cirrhosis

All of the following must be met as a condition for coverage:

  • Patient must have compensated liver disease by fibroscan ultrasound or biopsy, documenting stage 2, stage 3, or stage 4
  • Resistance testing must be included with the prior authorization request for genotype 1.
    • Treatment failure associated with HCV resistance to newly developed direct-acting antiviral agents is not an uncommon occurrence and poses a substantial problem to clinicians trying to re-treat patients who have failed available interferon-free treatments.
  • Patient must have FDA recognized contraindication to use of Zepatier

This Medication is Not Approvable for the following condition(s):

  • Patients with Stage 0 or stage 1 fibrosis
  • Any condition not listed above as an approved indication

Fibrosis

  • Stage 0 or 1 none or mild peri-portal fibrosis – not approvable
  • Stage 2 peri-portal fibrosis with/without extension and portal-portal bridging – approvable
  • Stage 3 portal-central bridges but no nodular formation - approvable
  • Stage 4 definite cirrhosis – approvable

Dosing:

  • Immediate-release (Viekira Pak):  Ombitasvir/paritaprevir/ritonavir tablet:  2 tablets every morning.  Dasabuvir tablet:  1 tablet twice daily.
  • Extended-release:  3 tablets once daily

Duration of therapy:

  • Genotype 1a, 12 weeks (without cirrhosis); 24 weeks (with compensated cirrhosis [Child-Pugh class A]).  Based on prior treatment history, some patients with compensated cirrhosis may be considered for a duration of therapy of 12 weeks.
  • Genotype 1b, 12 weeks (with or without compensated cirrhosis [Child-Pugh class A])
  • Genotype 1, unknown subtype or mixed infection:  12 weeks (without cirrhosis); 24 weeks (with compensated cirrhosis [Child-Pugh class A]).  Based on prior treatment history, some patients with compensated cirrhosis may be considered for a duration of therapy of 12 weeks.
  • Liver transplant recipients (Metavir fibrosis score 2 or less), regardless of genotype 1 subtype:  24 weeks.

Concomitant therapy: 

  • Use in combination with ribavirin for patients with genotype 1a (with or without compensated cirrhosis [Child-Pugh class A]), genotype 1 subtype unknown or mixed infection, and liver transplant recipients (Metavir fibrosis score 2 or less; regardless of genotype 1 subtype).

 


 

Last review date: March 2, 2015

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar